Drug intelligence / Profile preview

selinexor + venetoclax

Development stage: Unknown
Lead developer: Karyopharm Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy of selinexor (an XPO1 inhibitor) and venetoclax (a BCL2 inhibitor). Selinexor prevents the nuclear export of tumor suppressor proteins by inhibiting exportin-1 (XPO1), causing their accumulation in the nucleus and promoting cancer cell death. Venetoclax selectively binds to BCL2, blocking its antiapoptotic function and promoting apoptosis. The combination has shown synergistic effects in various hematological malignancies, particularly in multiple myeloma with t(11;14) translocation, acute myeloid leukemia, and mantle cell lymphoma.

Brand names: VenclextaXpovioVenclyxtoNexpovio
Other names: Venetoclax + SelenisolVinaclatSelenisol

Targets

XPO1 (Exportin-1)

Beyond the preview

Go deeper on selinexor + venetoclax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on selinexor + venetoclax.

Explore the full profile